Кардиопротекторные средства с биароматической структурой. Часть 2. Блокаторы HCN-каналов
https://doi.org/10.37489/2587-7836-2022-2-03-10
Аннотация
Управляемые циклическими нуклеотидами гиперполяризационно-активируемые каналы (HCN-каналы), прежде всего, их HCN4-подтип, являются одной из перспективных мишеней для разработки кардиопротекторных средств. Блокаторы HCN-каналов обладают селективным брадикардическим действием, сохраняя сократимость миокарда и диастолическую функцию и не оказывая влияния на электрофизиологические параметры сердца. Настоящий обзор продолжает серию обзоров по анализу соединений с кардиопротекторными свойствами в ряду биароматических структур, к которым относится и широкий ряд блокаторов HCN-каналов.
Об авторе
Г. В. Мокров
ФГБНУ «НИИ фармакологии имени В.В. Закусова»
Россия
Россия
Мокров Григорий Владимирович, к. х. н., в. н. с. лаборатории тонкого органического синтеза отдела химии лекарственных средств. SPIN-код: 8755-7666
Москва
Список литературы
1. Postea O, Biel M. Exploring HCN channels as novel drug targets. Nat Rev Drug Discov. 2011;10(12):903–914. DOI: 10.1038/NRD3576.
2. Larsson HP. How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle. J Gen Physiol. 2010;136(3):237–241. DOI: 10.1085/JGP.201010506.
3. Cao Y, Pang J, Zhou P. HCN channel as therapeutic targets for heart failure and pain. Curr Top Med Chem. 2015;16(16):1855–1861. DOI: 10.2174/1568026616666151215104058.
4. Roubille F, Tardif JC. New therapeutic targets in cardiology. Circulation. 2013;127(19):1986–1996. DOI:10.1161/CIRCULATIONAHA.112.000145.
5. Romanelli MN, Sartiani L, Masi A, et al. HCN channels modulators: the need for selectivity. Curr Top Med Chem. 2016;16(16):1764. DOI: 10.2174/1568026616999160315130832.
6. Мокров Г.В. Кардиопротекторные средства с биароматической структурой. Часть 1. Блокаторы кальциевых каналов. Фармакокинетика и Фармакодинамика. 2022;(4):3-17. DOI: 10.37489/2587-7836-2021-4-3-17.
7. Reiffen M, Eberlein W, Mueller P, et al. Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a new class of compounds exerting antiischemic properties. J Med Chem. 1990;33(5):1496–1504. DOI: 10.1021/JM00167A033.
8. Goethals M, Raes A, Bogaert PP van. Use-dependent block of the pacemaker current I(f) in rabbit sinoatrial node cells by zatebradine (UL-FS 49). On the mode of action of sinus node inhibitors. Circulation. 1993;88(5):2389–2401. DOI: 10.1161/01.CIR.88.5.2389.
9. Glasser SP, Michie DD, Thadani U, Baiker WM. Effects of zatebradine (ULFS 49 CL), a sinus node inhibitor, on heart rate and exercise duration in chronic stable angina pectoris. Am J Cardiol. 1997;79(10):1401–1405. DOI: 10.1016/S000-2914(99)X0015-0.
10. Bomhard A, Reiffen M, Heider J, Psiorz M, Lillie C. Specific bradycardic agents. 2. Heteroaromatic modifications in the side chain of specific bradycardic benzazepinones: chemistry, pharmacology, and structure-activity relationships. J Med Chem. 1991;34(3):942–947. DOI: 10.1021/JM00107A011.
11. Lillie C, Kobinger W. US Patent 5175157. 1990;352(552).
12. Granetzny A, Schwanke U, Schmitz C, et al. Pharmacologic heart rate reduction: effect of a novel, specific bradycardic agent on the heart. Thorac Cardiovasc Surg. 1998;46(02):63–69. DOI: 10.1055/S-2007-1010191.
13. Van Bogaert PP, Pittoors F. Use-dependent blockade of cardiac pacemaker current (If) by cilobradine and zatebradine. Eur J Pharmacol. 2003;478(2-3):161–171. DOI: 10.1016/J.EJPHAR.2003.08.083.
14. Stieber J, Wieland K, Stöckl G, Ludwig A, Hofmann F. Bradycardic and proarrhythmic properties of sinus node inhibitors. Mol Pharmacol. 2006;69(4):1328–1337. DOI: 10.1124/MOL.105.020701.
15. Vélez de Mendizábal N, Staab A, Schäfer HG, et al. Joint population pharmacokinetic/pharmacodynamic model for the heart rate effects at rest and at the end of exercise for cilobradine. Pharm Res. 2012;30(4):1110–1122. DOI: 10.1007/S11095-012-0947-6.
16. Kakefuda A, Watanabe T, Taguchi Y, Masuda N, Tanaka A, Yanagisawa I. Synthesis and pharmacological evaluation of 2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinoline derivatives as specific bradycardic agents. Chem Pharm Bull. 2003;51(4):390–398. DOI: 10.1248/CPB.51.390.
17. Kubota H, Kakefuda A, Watanabe T, et al. (±)-2-(3-Piperidyl)-1,2,3,4-tetrahydroisoquinolines as a new class of specific bradycardic agents. Bioorg Med Chem Lett. 2003;13(13):2155–2158. DOI: 10.1016/S0960-894X(03)00349-4.
18. Kubota H, Kakefuda A, Watanabe T, et al. Synthesis and Pharmacological evaluation of 1-Oxo-2-(3-piperidyl)-1,2,3,4-tetrahydroisoquinolines and related analogues as a new class of specific bradycardic agents possessing if channel inhibitory activity. J Med Chem. 2003;46(22):4728–4740. DOI: 10.1021/JM0301742.
19. Kubota H, Watanabe T, Kakefuda A, et al. Synthesis and pharmacological evaluation of N-acyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel specific bradycardic agents. Bioorg Med Chem. 2004;12(5):871–882. DOI: 10.1016/J.BMC.2003.12.032.
20. Umehara KI, Susaki Y, van Teylingen RHJ, et al. Evaluation of the inhibitory and induction potential of YM758, a novel If channel inhibitor, for human P450-mediated metabolism. Eur J Drug Metab Pharmacokinet. 2008;33(4):211–223. DOI: 10.1007/BF03190875.
21. Nakada N. Investigation of metabolite profile of YM758, a novel if channel inhibitor. Drugs R D. 2016;16(2):205–216. DOI: 10.1007/S40268-016-0130-3.
22. Peglion JL, Vian J, Vilaine JP, Villeneuve N, Janiak P, Bidouard JP. US Patent 5296482. Published online 1994.
23. Thollon C, Bedut S, Villeneuve N, et al. Use-dependent inhibition of hHCN4 by ivabradine and relationship with reduction in pacemaker activity. Br J Pharmacol. 2007;150(1):37–46. DOI: 10.1038/SJ.BJP.0706940.
24. Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP. Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994;112(1):37–42. DOI: 10.1111/J.1476-5381.1994.TB13025.X.
25. Simon L, Ghaleh B, Puybasset L, Giudicelli JF, Berdeaux A. Coronary and hemodynamic effects of S 16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther. 1995;275(2):659–666.
26. Gardiner SM, Kemp PA, March JE, Bennett T. Acute and chronic cardiac and regional haemodynamic effects of the novel bradycardic agent, S16257, in conscious rats. Br J Pharmacol. 1995;115(4):579–586. DOI: 10.1111/J.1476-5381.1995.TB14971.X.
27. Psotka MA, Teerlink JR. Ivabradine. Circulation. 2016;133(21):2066–2075. DOI: 10.1161/CIRCULATIONAHA.115.018094.
28. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur J Heart Fail. 2016;18(8):891–975. DOI: 10.1002/EJHF.592.
29. Chen C, Kaur G, Mehta PK, et al. Ivabradine in Cardiovascular Disease Management Revisited: a Review. Cardiovasc Drugs Ther. 2021;35(5):1045–1056. DOI: 10.1007/S10557-020-07124-4.
30. Peglion JL, Goument B, Dessinges A, et al. US Patent 8076325 B2. Published online 2011.
31. Bom A, Booth S, Bruin J, Clark J, Miller S, Wathey B. Parallel solid-phase synthesis of zatebradine analogues as potential I(f) channel blockers. Bioorg Med Chem Lett. 2001;11(17):2351–2354. DOI: 10.1016/S0960-894X(01)00424-3.
32. Romanelli MN, Cerbai E, Dei S, et al. Design, synthesis and preliminary biological evaluation of zatebradine analogues as potential blockers of the hyperpolarization-activated current. Bioorg Med Chem. 2005;13(4):1211–1220. DOI: 10.1016/J.BMC.2004.11.017.
33. Melchiorre M, Lungo M Del, Guandalini L, et al. Design, synthesis, and preliminary biological evaluation of new isoform-selective f-current blockers. J Med Chem. 2010;53(18):6773–6777. DOI: 10.1021/JM1006758.
34. Del Lungo M, Melchiorre M, Guandalini L, et al. Novel blockers of hyperpolarization-activated current with isoform selectivity in recombinant cells and native tissue. Br J Pharmacol. 2012;166(2):602–616. DOI: 10.1111/j.1476-5381.2011.01782.x.
35. Rieu JP, Duflos A, Tristani JC, et al. Synthesis and bradycardic activity of a series of substituted 3-Aminoalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones as potent antiischemics. Eur J Med Chem. 1993;28(9):683–691. DOI: 10.1002/CHIN.199404190.
Рецензия
Для цитирования:
Мокров Г.В. Кардиопротекторные средства с биароматической структурой. Часть 2. Блокаторы HCN-каналов. Фармакокинетика и Фармакодинамика. 2022;(2):3-10. https://doi.org/10.37489/2587-7836-2022-2-03-10
For citation:
Mokrov G.V. Сardioprotective agents with biaromatic structure. Part 2. HCN channel blockers. Pharmacokinetics and Pharmacodynamics. 2022;(2):3-10. (In Russ.) https://doi.org/10.37489/2587-7836-2022-2-03-10
Просмотров: 361
Послать статью по эл. почте 